# Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01619059` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01619059](<https://clinicaltrials.gov/study/NCT01619059>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01619059

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

## Technical summary

Registry record NCT01619059. Randomized; triple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2016-03-17.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 315 participants (enrolled count; ClinicalTrials.gov record NCT01619059, source copy `cardio:ctgov-nct01619059-2016-04-22`, retrieved 2026-10-26)
- Start date: 2012-06 (registry gives no type) (ClinicalTrials.gov record NCT01619059, source copy `cardio:ctgov-nct01619059-2016-04-22`, retrieved 2026-10-26)
- Primary completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01619059, source copy `cardio:ctgov-nct01619059-2016-04-22`, retrieved 2026-10-26)
- Completion: 2015-01 (actual) (ClinicalTrials.gov record NCT01619059, source copy `cardio:ctgov-nct01619059-2016-04-22`, retrieved 2026-10-26)
- Results first posted: 2016-03-17 (ClinicalTrials.gov record NCT01619059, source copy `cardio:ctgov-nct01619059-2016-04-22`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Hungary; Mexico; Poland; Puerto Rico; Romania; Russia (ClinicalTrials.gov record NCT01619059, source copy `cardio:ctgov-nct01619059-2016-04-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01619059-2016-04-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Saxagliptin
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Metformin IR
- Intervention (Drug): Placebo matching with Saxagliptin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes (`cardio:pubmed-26324329`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c201179bb3ac98d704887fe77cadaf1511c33ac7f58cf4f23c6e5e873cc4a077
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
